Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sacubitril/valsartan - Novartis

Next Previous
X
Search
Drug Profile

Sacubitril/valsartan - Novartis

Alternative Names: AHU-377/valsartan; dapagliflozin - Novartis; Enrest; Enresuto; Entresto; ENTRESTO SPRINKLE; LCZ-696; LCZ-696A; Neparvis; Valsartan/AHU-377; Valsartan/sacubitril

Latest Information Update: 13 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Rovi
  • Class Antihypertensives; Biphenyl compounds; Branched-chain amino acids; Cardiovascular therapies; Erectile dysfunction therapies; Esters; Heart failure therapies; Pentanoic acids; Small molecules; Tetrazoles; Urologics
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension; Heart failure; Hypertension
  • Phase III Erectile dysfunction; Kidney disorders
  • Phase II Hypertrophic cardiomyopathy

Most Recent Events

  • 14 Aug 2024 Novartis Pharmaceuticals completes a phase III trial in Heart failure (In adolescents, In children) in Japan (PO, capsule) (NCT06149104 )
  • 12 Apr 2024 Registered for Heart failure (In adolescents, In children, In infants) in USA (PO)
  • 01 Feb 2024 Novartis plans a phase III trial for Hypertension (Treatment naïve, Monotherapy, Combination therapy) (PO, Tablet) (NCT06236061)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top